PowerShares Dynamic Biotech & Genome Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 10 of 10 Posts
The Landscape Of Biotech ETFs
Article By: Nancy Zhang Tuesday, January 8, 2019 2:17 AM EDT
The challenge is to create a quality biotech index with a rule-based system, so the picking and re-balancing are handy and quick.
In this article: IBB, PBE, BBC, CNCR
Should You Invest In The Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Article By: Sweta Killa Thursday, November 22, 2018 1:05 PM EDT
Investor-friendly, sector ETFs provide many options to gain low risk and diversified exposure to a broad group of companies in particular sectors.
In this article: PBE Also: IBB, AMGN, BIIB, VRTX, XBI
M&A Waves Pushing Biotech ETFs Higher
Article By: Sweta Killa Thursday, January 18, 2018 2:16 PM EDT
The biotech corner of the broad healthcare sector is in the spotlight to start the New Year, as the new tax legislation has enticed U.S. companies to bring offshore cash back home, sparking waves of mergers and acquisitions.
In this article: FBT, PBE, BBC, CNCR Also: CELG, JUNO
4 Frightful ETFs Of This Year
Article By: Zacks Investment Research Thursday, October 27, 2016 3:38 PM EDT
Solar stocks are victims of the general misconception that oil price and solar market fundamentals are directly related to each other. Further, weak earnings from a few industry bellwethers weighed on solar ETFs.
In this article: KWT, BBC, SBIO, PBE Also: VXX, VIXY, VIIX, TAPR, TAN
Biotech ETF Industry Outlook
Article By: Zacks Investment Research Sunday, September 4, 2016 7:29 PM EDT
Sector-specific issues like increasing political and media focus on high price tags for new drugs and the changing competitive scenario have been weighing on biotech stocks over the last few quarters but the sector’s fundamentals remain strong.
In this article: IBB, BBH, FBT, PBE, XBI
What Lies Ahead For Biotech ETFs In 2016?
Article By: Zacks Investment Research Saturday, January 9, 2016 6:51 PM EDT
It has been a highly eventful year for the biotech sector thanks to mergers and acquisitions (M&A), deals galore, pricing controversy, stretched valuations and the usual pipeline updates. The NASDAQ Biotechnology index is up 7.7% YTD.
In this article: IBB, BBH, FBT, PBE, XBI
Biotech ETFs In Focus After A Choppy Week
Article By: Zacks Investment Research Tuesday, March 31, 2015 11:30 PM EDT
Biotech stocks were able to keep their rally intact until March 25, breezing past the nearly flat broader market indices. However, on March 25, major biotechnology indexes were off over 4%, leading the Nasdaq Composite Index to see its biggest ‘one-day loss in nearly a year’.
In this article: IBB, SPY, BBH, FBT, XBI, PBE, SBIO
Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs
Article By: Zacks Investment Research Friday, February 6, 2015 4:15 AM EDT
The biotech sector stood out last year and the NASDAQ Biotechnology Index delivered a stellar 34% return for 2014.
In this article: GILD, AMGN, BIIB, ALXN, IBB, BBH, PBE
3 Biotech ETF Winners From 2014's Best Performing Sector
Article By: Zacks Investment Research Wednesday, January 7, 2015 4:04 AM EDT
The NASDAQ Biotechnology index delivered a stellar 34% return in 2014 – emerging as the biggest winner among all the sectors.
In this article: SPX, FBT, XBI, PBE
Bullish Conviction Returns, But Market Likely To Consolidate Its V-Bottom
Article By: Sabrient Systems Monday, October 27, 2014 9:14 AM EDT
Bulls showed renewed backbone last week and drew a line in the sand for the bears, buying with gusto into weakness as I suggested they would.
1 to 10 of 10 Posts